# Progress Note 04 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Wilma Rudolph (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML036-SYN
- Date: 2026-09-14
- Fictional facility: St. Posthumous Health Center
- Fictional author: Gloria Haynes-Whitaker, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Review at the end of six weeks of radiotherapy with daily temozolomide. **S**

## History of present illness

Ms. Rudolph returns on the first weekday after her last radiotherapy fraction. She completed all 30 fractions and took temozolomide every day without a break, the 42nd and last dose last night. Nausea was mild and controlled by ondansetron before each dose. She stopped dexamethasone a month ago and her fingerstick glucose readings came back below 120 mg/dL, so she stopped checking. She is more tired each week, sleeps after lunch and has worked only a few hours a day for the past two weeks. Her hair has fallen out over the treated area and the skin there is pink. She has had no headache, seizure, change in speech, weakness, fever, bruising, cough or fall. The weekly blood counts at the radiation clinic were normal in the first five weeks; the week 6 count was not drawn. She has read about tumor-treating fields and wants to talk about them. She has had no thoughts of self-harm. **S**

| Element | Detail |
|---|---|
| Treatment | Radiotherapy 60 Gy in 30 fractions and 42 days of temozolomide completed on schedule |
| Steroid | Off dexamethasone for a month; glucose normal |
| Symptoms | Fatigue, mild nausea, hair loss and pink skin over the field |
| Blood counts | Normal for five weeks; week 6 not drawn |
| Her question | Whether to use tumor-treating fields |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Fatigue, worse each week; no fever; weight down 2.2 kg since the steroid stopped |
| Gastrointestinal | Positive | Mild nausea after the doses, controlled; no vomiting; no constipation |
| Integumentary | Positive | Hair loss over the treated area; pink scalp without blisters |
| Neurological | Negative | No headache, seizure, speech change or new weakness |
| Hematologic and lymphatic | Negative | No bruising, nosebleeds or gum bleeding |
| Respiratory | Negative | No cough or breathlessness |
| Psychiatric | Positive | Low in energy and sometimes discouraged; PHQ-9 8, mostly from tiredness and sleep; no thoughts of self-harm |

7 systems reviewed. **S**

## Current medications

- Acetaminophen 500 mg oral tablet, two tablets by mouth every 6 hours as needed for headache, no more than 3 g a day **S**
- Sulfamethoxazole 800 mg and trimethoprim 160 mg oral tablet, one tablet three times a week (Monday, Wednesday and Friday) to prevent Pneumocystis pneumonia **S**
- Ondansetron 8 mg oral tablet, one tablet 30 to 60 minutes before each temozolomide dose, and every 8 hours as needed for nausea **S**

## Allergies

- No known allergy **S**

## Objective

BP 118/74 mmHg; pulse 80 bpm; respirations 16/min; temperature 36.8 °C; oxygen saturation 98% on room air; weight 67.2 kg; BMI 20.7 kg/m². All vital signs are synthetic.

Hemoglobin: 11.9 g/dL (low); White cell count: 3.6 10*3/uL (low); Absolute neutrophil count: 2.4 10*3/uL; Absolute lymphocyte count: 0.5 10*3/uL (low); Platelets: 112 10*3/uL (low); Creatinine: 0.8 mg/dL; eGFR (CKD-EPI 2021): 88 mL/min/1.73 m²; ALT: 48 U/L (high); AST: 39 U/L (high); Total bilirubin: 0.6 mg/dL; Glucose: 96 mg/dL; Karnofsky Performance Status: 80; PHQ-9: 8. All results are synthetic.

## Change since baseline

- Hemoglobin: 13.1 g/dL at baseline, 11.9 g/dL (low) at this visit **S**
- White cell count: 7.1 10*3/uL at baseline, 3.6 10*3/uL (low) at this visit **S**
- Platelets: 262 10*3/uL at baseline, 112 10*3/uL (low) at this visit **S**
- Creatinine: 0.86 mg/dL at baseline, 0.8 mg/dL at this visit **S**
- eGFR (CKD-EPI 2021): 80 mL/min/1.73 m² at baseline, 88 mL/min/1.73 m² at this visit **S**
- Glucose: 92 mg/dL at baseline, 96 mg/dL at this visit **S**
- Karnofsky Performance Status: 80 at baseline, 80 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Tired but well; weight 67.2 kg; blood pressure 118/74, pulse 80, temperature 36.8 °C |
| Head | Alopecia over the left frontal field; grade 1 radiation dermatitis; incision healed |
| Mouth | No ulcers or thrush |
| Skin | No bruising or petechiae |
| Neurological | Speech fluent; strength full in all four limbs; finger tapping equal; gait steady |
| Extremities | No leg swelling or calf tenderness |
| Psychiatric | Tired, warm and engaged |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Glioblastoma, IDH-wildtype, MGMT methylated, after chemoradiation** (C71.1). Chemoradiation completed on schedule. Platelets 112 (grade 1) and white cells 3.6 with neutrophils 2.4 are expected at the end of daily temozolomide and will recover during the four-week break. ALT 48 and AST 39 U/L are a grade 1 rise, common with temozolomide; to be rechecked before adjuvant treatment. Fatigue at this point is mainly from radiotherapy and should ease over the coming weeks. We discussed tumor-treating fields: in the EF-14 trial, adding them to adjuvant temozolomide lengthened survival, at the cost of wearing scalp arrays at least 18 hours a day and possible skin irritation. She chose to start them with adjuvant temozolomide. **S**
   - Four-week break from temozolomide.
   - MRI of the brain with contrast in about three weeks.
   - Adjuvant temozolomide 150 mg/m2 on days 1 to 5, cycle 1 after the MRI, if neutrophils are at least 1.5 and platelets at least 100.
   - Tumor-treating fields device fitting arranged to start with cycle 1.
   - Palliative care referral now, alongside treatment.
2. **Lymphopenia from temozolomide, grade 2** (D72.810). Absolute lymphocytes 0.5: the label calls for Pneumocystis prophylaxis to continue until lymphopenia recovers to grade 1 or better. **S**
   - Continue sulfamethoxazole-trimethoprim three times a week.
   - Lymphocytes with each blood count.
3. **Steroid-induced hyperglycemia** (R73.9). Glucose 96 mg/dL a month after the last dexamethasone dose; resolved. **S**
   - Problem resolved; recheck glucose if steroids are needed again.
4. **Late effects of childhood poliomyelitis** (B91). No fall; legs strong; fatigue is explained by treatment rather than a new post-polio pattern, since there is no new weakness, muscle pain or intolerance of cold in the left leg. **S**
   - Continue home exercises at a gentler level; rest breaks.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Blood count with neutrophils, lymphocytes and platelets | Weekly during concurrent temozolomide | Completed today | Hemoglobin 11.9 g/dL, white cells 3.6, neutrophils 2.4, lymphocytes 0.5, platelets 112: grade 1 thrombocytopenia and grade 2 lymphopenia |
| Laboratory | Blood count in week 6 of concurrent treatment | Weekly during concurrent temozolomide | Deferred | A deviation: not drawn in the last week of radiotherapy because the clinic's standing order was set for the Monday, a holiday that week, and was not moved. No harm resulted: today's count, a week later, shows platelets 112 and neutrophils 2.4, above the levels that would have stopped temozolomide, and she had no bleeding or fever. Corrective action: today's count; future standing orders are tied to treatment days, not a weekday |
| Laboratory | Liver tests (ALT, AST, bilirubin) | Baseline, during treatment, before each cycle, and two to four weeks after the last dose | Completed today | ALT 48, AST 39 U/L (grade 1), bilirubin 0.6 mg/dL; recheck before cycle 1 |
| Laboratory | Kidney function and glucose | Each visit; glucose after a steroid course | Completed today | Creatinine 0.80 mg/dL, eGFR 88; glucose 96 mg/dL off dexamethasone |
| Laboratory | Hepatitis B, hepatitis C and HIV screening | Before chemotherapy | Up to date | All negative |
| Medication safety | Pneumocystis pneumonia prophylaxis | During concurrent temozolomide, and until lymphopenia is grade 1 or better | Completed today | Taken as prescribed without rash; continues for grade 2 lymphopenia |
| Medication safety | Antiemetic before temozolomide | Each dose | Completed today | Ondansetron effective; no vomiting |
| Imaging | MRI of the brain after chemoradiation | About four weeks after radiotherapy, as the new baseline | Ordered | In about three weeks; enhancement in the first three months may be treatment effect (pseudoprogression) and is read by RANO 2.0 |
| Examination | Neurologic examination (language, strength, gait) | Each visit | Completed today | No deficit; speech fluent; strength full |
| Examination | Radiation skin reaction and hair loss | Weekly during radiotherapy and at the end | Completed today | Grade 1 dermatitis; alopecia over the field |
| Medication safety | Seizure history and antiseizure drug need | Each visit | Not indicated | No seizure; no antiseizure drug |
| Examination | Signs of leg clot or pulmonary embolism | Each visit | Completed today | None |
| Survey | Performance status (Karnofsky) | Each visit | Completed today | Karnofsky 80, from fatigue |
| Self-management | Tumor-treating fields | Offered with adjuvant temozolomide for supratentorial glioblastoma | Completed today | Benefits, daily wear and skin effects discussed; she chose to start them with cycle 1 |
| Referral | Palliative care | Early, alongside cancer treatment, for a serious illness with a high symptom burden | Referred | Outpatient consultation booked in two weeks |
| Self-management | Falls, leg strength and late effects of polio | Each visit | Completed today | No falls; home exercises at a gentler level; cane on uneven ground |
| Survey | Distress and depression screen (PHQ-9) | At diagnosis, each treatment phase, and when symptoms change | Completed today | PHQ-9 8, mostly from fatigue and sleep; no thoughts of self-harm |

## Goal progress

- MRI of the brain within 24 hours and a neuro-oncology and neurosurgery plan within one week of presentation. Outcome by 2026-07-02: MRI the next morning; consultation three days after the first visit. **S**
- Maximal safe resection within two weeks of the MRI, preserving language and right-hand strength. Outcome by 2026-07-29: Gross total resection of the enhancing tumor nine days after the first visit; speech back to normal within days and right-hand strength nearly normal. **S**
- Radiotherapy with daily temozolomide started within six weeks of surgery and completed on schedule. Outcome by 2026-09-14: Started 26 days after surgery; 30 fractions and 42 days of temozolomide completed without a break. **S**
- Dexamethasone tapered off within five weeks of surgery, with glucose back to normal. Outcome by 2026-09-14: Off dexamethasone five weeks after surgery; glucose 96 mg/dL afterwards. **S**
- No falls, and walking independently, through treatment. In progress; target 2026-10-09. **S**
- Palliative care involved and her wishes recorded before adjuvant treatment begins. In progress; target 2026-10-09. **S**

## Guideline basis

- NCCN Clinical Practice Guidelines in Oncology: Central Nervous System Cancers (2026), National Comprehensive Cancer Network
- Weller M, et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol 2021;18(3):170-186 (PMID 33293629) (2021), European Association of Neuro-Oncology
- Stupp R, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352(10):987-996 (PMID 15758009) (2005), New England Journal of Medicine
- Stupp R, et al. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma (EF-14). JAMA 2017;318(23):2306-2316 (PMID 29260225) (2017), JAMA
- Wen PY, et al. RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults. J Clin Oncol 2023 (PMID 37774317) (2023), Response Assessment in Neuro-Oncology working group (Journal of Clinical Oncology)
- TEMODAR (temozolomide) capsules, prescribing information (2026), U.S. National Library of Medicine, DailyMed (Merck Sharp & Dohme label)
- Walbert T, et al. SNO and EANO practice guideline update: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Neuro Oncol 2021;23(11):1835-1844 (PMID 34174071) (2021), Society for Neuro-Oncology and European Association of Neuro-Oncology
- Key NS, et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Guideline Update. J Clin Oncol 2023;41(16):3063-3071 (PMID 37075273) (2023), American Society of Clinical Oncology
- Sanders JJ, et al. Palliative Care for Patients With Cancer: ASCO Guideline Update. J Clin Oncol 2024;42(19):2336-2357 (PMID 38748941) (2024), American Society of Clinical Oncology
- Farbu E, et al. EFNS guideline on diagnosis and management of post-polio syndrome. Eur J Neurol 2006;13(8):795-801 (PMID 16879288) (2006), European Federation of Neurological Societies
- CMID: Clinical Monitoring Intelligence Database, depression monograph (2026), Aether Forge
- Depression and Suicide Risk in Adults: Screening (2023), U.S. Preventive Services Task Force

## Follow-up

- MRI in about three weeks; palliative care in two weeks. Review with the MRI result on the day adjuvant temozolomide starts. Call for fever, bruising, bleeding, a seizure, headache or new weakness. **S**
- Next scheduled visit 2026-10-09: post-chemoradiation MRI result, day 1 of adjuvant temozolomide, the start of tumor-treating fields, and the palliative care plan. **S**
